PD-016Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. (2nd July 2019) - Raimondi, A; Di Maio, M; Peverelli, G; Morano, F; Corallo, S; Bergamo, F; Cremolini, C; Smiroldo, V; Amatu, A; Tampellini, M; Fanchini, L; Murialdo, R; et al.